Thursday, 13 July 2017
Friday, 14 July 2017

Registration & Networking Breakfast in Exhibition Hall

Chairperson’s Opening Remarks

Kazumi Fujikawa, VP, Market Data Management, Global Commercial, Takeda Pharmaceuticals

Keynote: Ready to Transform?

Osamu Karita, Senior Partner and Managing Director, The Boston Consulting Group

• Latest trends in the pharma industry

• What has driven the pharma industry?
• What are the key trends, challenges and opportunities facing the industry?
• What are the implications for pharma companies?

Keynote Panel Discussion and Q&A

Kazumi Fujikawa, VP, Market Data Management, Global Commercial, Takeda Pharmaceuticals
Osamu Karita, Senior Partner and Managing Director, The Boston Consulting Group

Networking & Refreshments in Exhibition Hall

Networking Round Table Discussions

(participants may choose any round table to attend)
Social Media and CI
Laiza Filart, Regional Director, New Product Marketing and Business Intelligence, A. Menarini Asia-Pacific
Building a Community of Insights
Carlos Hernandez, Head of Market Insights, Abbott Laboratories

Networking Luncheon

HCP’s Social Media Tracking in China

Hanson Zheng, Senior Director, Customer Insight & Innovation, Bristol-Myers Squibb

The Opportunities from the Latest Digital-Health Policy of China

Anne Chi, President, SAI Asia

The presentation will cover the latest government policy that provides the blueprint of the Chinese government’s plan in the sharing, use and management of big data.

In this presentation, SAI will also provide the analysis of the opportunities presented from the policy and how pharmaceutical and med devices companies need to re-assess the strategy toward the new era. Details covered by the presentation include:

• How the policy pave the way for digital applications in the dynamic Chinese healthcare industry

• New players and alliance opportunities emerged from optimization, sharing and management of big data in the healthcare industry

• Opportunities to enhance operation excellence at the pharmaceutical/med devices companies and hospital management

• Impact on patient management programs

• Impact on market access

• How the new digital era needs to play a role in the business strategy at pharmaceuticals and devices (medical/wearable) companies

CI Strategies in Niche Therapeutic Segments

Veena Swaminathan, Integrated Solutions and Stakeholders Insights Lead, Sanofi Genzyme

• Rare diseases / orphan drugs are a segment which are not tracked by most data companies

• Thus, there is limited 3rd party, objective data on rare diseases
• This is more pronounced in emerging markets like Asia, where information for big pharma is sketchy at best
• The above scenario results in utilization of different strategies to determine the competitive landscape; techniques less frequently if ever used in big pharma

Networking & Refreshments in Exhibition Hall

Turn Down the Science and Turn Up the Feeling. Building Brands with Doctors

Carlos Hernandez, Head of Market Insights, Abbott Laboratories
Maria Spinelli, Senior Vice President, Asia, System1 Research

Update on the US Generic Drug Industry – Opportunities and Challenges

Margaret Hsiao, CEO & Co-Founder, Harvest Moon Pharmaceuticals

• The New President Trump Administration - effect on the US generic drug industry

• FDA issues, ongoing mergers, biosimilars opportunity, recent news
• US FDA compliance issues with companies in India
• The rise of China and Japan as a player in US generic Drug industry

Adapting Market Access Strategies in China Local Diversity Environment from CI Perspective

Xuan Cui, Head, Strategic Policy & Access, Sanofi China

Integrating Market Research and Competitive Intelligence to Harness Actionable Insight in the Biopharmaceutical Sector

Dr. Daniel Pascheles, CEO, Molekule Consulting

• The practice of biopharmaceutical market research and competitive intelligence are not mutually exclusive. Although both practice areas are distinct – meaningful overlap exists.

• This talk discusses how to build “best practices” for your team, integrating relevant and complimentary functional roles and findings from MR and CI.
• By integrating key learnings from both practices, companies are able to harness strategic and actionable insight into the biopharmaceutical sector.

Evening Socializing Events! Cocktail Reception & Networking

Registration & Networking Breakfast in Exhibition Hall

An Introduction to Competitive Intelligence and Strategy

Ju Hyoung Lim, MSc, Ph.D., Senior Manager, JAPAC Operations, Deallus Consulting
Neal Somchand, MSc, Principal, JAPAC Operations, Deallus Consulting

In reality most Competitive Intelligence work is information driven and lack a real connection to decision making and

strategy. It is irrelevant to the business and operates in an organisational vacuum. This workshop will provide you an introduction to Competitive Intelligence, and how to run a demand driven and decision supportive competitive intelligence process that focus on understanding the competitive environment, the strategic intent and future initiatives of your key competitors and other market stakeholders. We will combine traditional training with some hands on exercises to help you implement our training in your day to day work back at the office, to ensure you are tightly connected to business imperatives and have a decisive impact on your business decision making and strategy.

Networking & Refreshments in Exhibition Hall

The Use of CI in Business Development Opportunity Assessments

Steven Robery, BSc, Ph.D., Senior Consultant, Lifescience Dynamics Limited
Shawn Xie, Senior Business Analyst, Lifescience Dynamics Limited

• How can CI support the BD&L process?

• How can MA and payer discussions complement CI in this process?
• How can Payer research input in the forecasting?
• Valuation of an asset using CI

Chairperson’s Closing Remarks

Kazumi Fujikawa, VP, Market Data Management, Global Commercial, Takeda Pharmaceuticals

Networking Luncheon

Conference Concludes